Zetao Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zetao Liao has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Jieruo Gu
Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
3 shared publications - Mingcan Yang
Third Affiliated Hospital of Sun Yat-Sen University
3 shared publications - Qing Lv
Department of Rheumatology The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China
3 shared publications - Yutong Jiang
Department of Rheumatology and Immunology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
3 shared publications - Jun Qi
Department of Rheumatology The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China
2 shared publications - Linkai Fang
Rheumatology and Immunology Department, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2 shared publications
Latest Publications
- 20 February 2023
- Published by Wiley in Arthritis Care & Research
- Vol. 75 (7) , 1503-1510
Associations Between Dietary Intake of Vitamin K and Changes in Symptomatic and Structural Changes in Patients With Knee Osteoarthritis
Objective: To investigate associations of dietary vitamin K intake with changes in knee symptoms and structures in patients with knee osteoarthritis (OA).Methods: Participants with symptomatic knee OA were enrolled (n = 259) and followed up for 2 years (n = 212). Baseline dietary vitamin K intake was calculated from a validated food frequency questionnaire. Knee symptoms were assessed by using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. Knee cartilage defects, bone marrow lesions, and effusion‐synovitis volume were measured from magnetic resonance imaging (MRI) scans. Univariable and multivariable linear regressions were used for analyses.Results: A higher vitamin K intake quartile was significantly associated with a greater decrease in the total WOMAC score and dysfunction score over 24 months. The subgroup analyses showed in patients with severe baseline visual analog scale (VAS) pain that a higher vitamin K intake quartile was associated with more improvement in all WOMAC scores. There were no overall significant associations between vitamin K intake and changes in MRI features. In subgroup analysis, vitamin K intake was negatively associated with changes in tibiofemoral, patellar, and total cartilage defects in participants with a severe baseline radiographic grade and was negatively associated with change in total and patellar cartilage defects in participants with severe baseline VAS pain and in female patients.Conclusion: The association of higher vitamin K intake with decreased knee symptoms over 24 months in patients with knee OA suggests that clinical trials examining the effect of vitamin K supplementation for knee OA symptoms are warranted. Whether there is an effect on knee structure is unclear.
- 20 February 2023
- Published by Wiley in Arthritis Care & Research
- Vol. 75 (7) , 1503-1510
Associations Between Dietary Intake of Vitamin K and Changes in Symptomatic and Structural Changes in Patients With Knee Osteoarthritis
Objective: To investigate associations of dietary vitamin K intake with changes in knee symptoms and structures in patients with knee osteoarthritis (OA).Methods: Participants with symptomatic knee OA were enrolled (n = 259) and followed up for 2 years (n = 212). Baseline dietary vitamin K intake was calculated from a validated food frequency questionnaire. Knee symptoms were assessed by using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. Knee cartilage defects, bone marrow lesions, and effusion‐synovitis volume were measured from magnetic resonance imaging (MRI) scans. Univariable and multivariable linear regressions were used for analyses.Results: A higher vitamin K intake quartile was significantly associated with a greater decrease in the total WOMAC score and dysfunction score over 24 months. The subgroup analyses showed in patients with severe baseline visual analog scale (VAS) pain that a higher vitamin K intake quartile was associated with more improvement in all WOMAC scores. There were no overall significant associations between vitamin K intake and changes in MRI features. In subgroup analysis, vitamin K intake was negatively associated with changes in tibiofemoral, patellar, and total cartilage defects in participants with a severe baseline radiographic grade and was negatively associated with change in total and patellar cartilage defects in participants with severe baseline VAS pain and in female patients.Conclusion: The association of higher vitamin K intake with decreased knee symptoms over 24 months in patients with knee OA suggests that clinical trials examining the effect of vitamin K supplementation for knee OA symptoms are warranted. Whether there is an effect on knee structure is unclear.
- Open Access
- 3 June 2019
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 7 (6) , e10299
Using Mobile Apps for Health Management: A New Health Care Mode in China
Background: China has a large population; however, medical resources are unevenly distributed and extremely limited, and more medical services are needed. With the development and ever-increasing popularity of mobile internet communication, China has created a mode of mobile health (mHealth) care to resolve this problem. Objective: The aim of this study was (1) to describe the problems associated with China’s medical care practice, (2) explore the need for and the feasibility of internet-based medical care in China, and (3) analyze the functionality of and services offered by internet-based health care platforms for the management of chronic diseases. Methods: Data search was performed by searching national websites, the popular search engine Baidu, the App Store, and websites of internet medical care institutions, using search terms like “mobile health,” “Internet health,” “mobile medical,” “Internet medical,” “digital medical,” “digital health,” and “online doctor.” A total of 6 mobile apps and websites with the biggest enrollment targeting doctors and end users with chronic diseases in China were selected. Results: We recognized the limitations of medical and health care providers and unequal distribution of medical resources in China. An mHealth care platform is a novel and efficient way for doctors and patients to follow up and manage chronic diseases. Services offered by these platforms include reservation and payment, medical consultation, medical education assessment, pharmaceutical and medical instruments sales, electronic medical records, and chronic disease management. China’s health policies are now strongly promoting the implementation of mHealth solutions, particularly in response to the increasing burden of chronic diseases and aging in the population. Conclusions: China's internet-based medical and health care mode can benefit the populace by providing people with high-quality medical resources. This can help other countries and regions with high population density and unevenly distributed medical resources manage their health care concerns.
- 3 June 2019
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 7 (6) , e10299
Open AccessUsing Mobile Apps for Health Management: A New Health Care Mode in China
Background: China has a large population; however, medical resources are unevenly distributed and extremely limited, and more medical services are needed. With the development and ever-increasing popularity of mobile internet communication, China has created a mode of mobile health (mHealth) care to resolve this problem. Objective: The aim of this study was (1) to describe the problems associated with China’s medical care practice, (2) explore the need for and the feasibility of internet-based medical care in China, and (3) analyze the functionality of and services offered by internet-based health care platforms for the management of chronic diseases. Methods: Data search was performed by searching national websites, the popular search engine Baidu, the App Store, and websites of internet medical care institutions, using search terms like “mobile health,” “Internet health,” “mobile medical,” “Internet medical,” “digital medical,” “digital health,” and “online doctor.” A total of 6 mobile apps and websites with the biggest enrollment targeting doctors and end users with chronic diseases in China were selected. Results: We recognized the limitations of medical and health care providers and unequal distribution of medical resources in China. An mHealth care platform is a novel and efficient way for doctors and patients to follow up and manage chronic diseases. Services offered by these platforms include reservation and payment, medical consultation, medical education assessment, pharmaceutical and medical instruments sales, electronic medical records, and chronic disease management. China’s health policies are now strongly promoting the implementation of mHealth solutions, particularly in response to the increasing burden of chronic diseases and aging in the population. Conclusions: China's internet-based medical and health care mode can benefit the populace by providing people with high-quality medical resources. This can help other countries and regions with high population density and unevenly distributed medical resources manage their health care concerns.
- Open Access
- 6 March 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Using Mobile Apps for Health Management: A New Health Care Mode in China (Preprint)
BACKGROUND China has a large population; however, medical resources are unevenly distributed and extremely limited, and more medical services are needed. With the development and ever-increasing popularity of mobile internet communication, China has created a mode of mobile health (mHealth) care to resolve this problem. OBJECTIVE The aim of this study was (1) to describe the problems associated with China’s medical care practice, (2) explore the need for and the feasibility of internet-based medical care in China, and (3) analyze the functionality of and services offered by internet-based health care platforms for the management of chronic diseases. METHODS Data search was performed by searching national websites, the popular search engine Baidu, the App Store, and websites of internet medical care institutions, using search terms like “mobile health,” “Internet health,” “mobile medical,” “Internet medical,” “digital medical,” “digital health,” and “online doctor.” A total of 6 mobile apps and websites with the biggest enrollment targeting doctors and end users with chronic diseases in China were selected. RESULTS We recognized the limitations of medical and health care providers and unequal distribution of medical resources in China. An mHealth care platform is a novel and efficient way for doctors and patients to follow up and manage chronic diseases. Services offered by these platforms include reservation and payment, medical consultation, medical education assessment, pharmaceutical and medical instruments sales, electronic medical records, and chronic disease management. China’s health policies are now strongly promoting the implementation of mHealth solutions, particularly in response to the increasing burden of chronic diseases and aging in the population. CONCLUSIONS China's internet-based medical and health care mode can benefit the populace by providing people with high-quality medical resources. This can help other countries and regions with high population density and unevenly distributed medical resources manage their health care concerns.
- 6 March 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessUsing Mobile Apps for Health Management: A New Health Care Mode in China (Preprint)
BACKGROUND China has a large population; however, medical resources are unevenly distributed and extremely limited, and more medical services are needed. With the development and ever-increasing popularity of mobile internet communication, China has created a mode of mobile health (mHealth) care to resolve this problem. OBJECTIVE The aim of this study was (1) to describe the problems associated with China’s medical care practice, (2) explore the need for and the feasibility of internet-based medical care in China, and (3) analyze the functionality of and services offered by internet-based health care platforms for the management of chronic diseases. METHODS Data search was performed by searching national websites, the popular search engine Baidu, the App Store, and websites of internet medical care institutions, using search terms like “mobile health,” “Internet health,” “mobile medical,” “Internet medical,” “digital medical,” “digital health,” and “online doctor.” A total of 6 mobile apps and websites with the biggest enrollment targeting doctors and end users with chronic diseases in China were selected. RESULTS We recognized the limitations of medical and health care providers and unequal distribution of medical resources in China. An mHealth care platform is a novel and efficient way for doctors and patients to follow up and manage chronic diseases. Services offered by these platforms include reservation and payment, medical consultation, medical education assessment, pharmaceutical and medical instruments sales, electronic medical records, and chronic disease management. China’s health policies are now strongly promoting the implementation of mHealth solutions, particularly in response to the increasing burden of chronic diseases and aging in the population. CONCLUSIONS China's internet-based medical and health care mode can benefit the populace by providing people with high-quality medical resources. This can help other countries and regions with high population density and unevenly distributed medical resources manage their health care concerns.
- Open Access
- 3 December 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-6
Complex Segregation Analysis Provides Evidence for Autosomal Dominant Transmission in the Chinese Han Families with Ankylosing Spondylitis
Introduction. Familial aggregation of ankylosing spondylitis (AS) has been frequently noticed. However, the mode of inheritance in AS remains poorly understood. Our aim was to determine the mode of inheritance best fitting the observed transmission pattern of AS families. Methods. Families with 5 or more AS patients diagnosed with 1984 modified New York criteria were recruited. We performed complex segregation analysis for a binary trait in regressive multivariate logistic models. The inheritance models, including sporadic, major gene, environmental, general, and other 9 models, were compared by likelihood ratio tests and Akaike’s Information Criterion. Results. This research included 9 Chinese Han AS families with a total number of 315 persons, including 74 patients. First, familial association was determined. Sporadic with familial association model was rejected when compared with either the general model or the homogeneous general model (). The environmental model was also rejected when compared with general models (). Mendelian dominate mode fitted best in 5 AS families, while Tau AB free model best explained the mode of inheritance in these AS families. Conclusion. This study provided evidence in support of Mendelian dominant mode and firstly discovered a non-Mendelian mode called tau AB free inheritance mode in AS.- 3 December 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-6
Open AccessComplex Segregation Analysis Provides Evidence for Autosomal Dominant Transmission in the Chinese Han Families with Ankylosing Spondylitis
Introduction. Familial aggregation of ankylosing spondylitis (AS) has been frequently noticed. However, the mode of inheritance in AS remains poorly understood. Our aim was to determine the mode of inheritance best fitting the observed transmission pattern of AS families. Methods. Families with 5 or more AS patients diagnosed with 1984 modified New York criteria were recruited. We performed complex segregation analysis for a binary trait in regressive multivariate logistic models. The inheritance models, including sporadic, major gene, environmental, general, and other 9 models, were compared by likelihood ratio tests and Akaike’s Information Criterion. Results. This research included 9 Chinese Han AS families with a total number of 315 persons, including 74 patients. First, familial association was determined. Sporadic with familial association model was rejected when compared with either the general model or the homogeneous general model (). The environmental model was also rejected when compared with general models (). Mendelian dominate mode fitted best in 5 AS families, while Tau AB free model best explained the mode of inheritance in these AS families. Conclusion. This study provided evidence in support of Mendelian dominant mode and firstly discovered a non-Mendelian mode called tau AB free inheritance mode in AS. - 1 June 2013
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (Suppl 3) , A513
FRI0413 Safety of etanercept therapy in hbsag carriers with ankylosing spondylitis: a prospective study
Background The prevalence rate of hepatitis B virus (HBV) infection in China (13%) and many other developing countries are much higher than that in developed countries. When anti-TNF agents are more available and affordable in developing countries, the safety of anti-TNF therapy in terms of the reactivation of hepatitis B virus (HBV) infection need more concern. Very few data from a prospective study focus on the use of TNF antagonists in patients with concurrent ankylosing spondylitis (AS) and HBV infection are available by now. Objectives To evaluate the influence of etanercept on the reactivation of HBV infection in HBsAg carriers with AS. Methods In this 48 weeks observation, HBsAg carriers with active AS (BASDAI ≥ 4 ) despite failed treatment with at least two NSAIDs and sulfasalazine (for patients with persistent peripheral arthritis) were studied. Patients must have normal liver function prior to etanercept therapy. All patients received the treatment of etanercept 50mg each week. For patients who had positive HBV load (>100 copy/ml) at baseline, lamivudin were prescribed preventively. Pre-existing NSAIDs and sulfasalazine were allowed. During the study, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and HBV load (polymerase chain reaction) were monitored every 6 weeks in the first 12 weeks and every 12 weeks after week 12. Increased AST/ALT and HBV load were managed and monitored according to expert opinion. After withdraw of etanercept due to any reason, monitoring of ALT, AST and HBV load must be conducted until normal result was obtained in 2 consecutive tests. Results Twenty-four patients (22 male, 1 female) were recruited. At baseline, seventeen patients (group 1, including 1 female) had normal viral load (Conclusions Etanercept therapy represent a safe and effective option for HBsAg carriers with AS refractory to traditional treatment. Prophylaxis strategy with more effective anti-viral drugs is recommended to reduce the risk of hepatitis B reactivation. Disclosure of Interest None Declared
- 1 June 2013
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (Suppl 3) , A513
FRI0413 Safety of etanercept therapy in hbsag carriers with ankylosing spondylitis: a prospective study
Background The prevalence rate of hepatitis B virus (HBV) infection in China (13%) and many other developing countries are much higher than that in developed countries. When anti-TNF agents are more available and affordable in developing countries, the safety of anti-TNF therapy in terms of the reactivation of hepatitis B virus (HBV) infection need more concern. Very few data from a prospective study focus on the use of TNF antagonists in patients with concurrent ankylosing spondylitis (AS) and HBV infection are available by now. Objectives To evaluate the influence of etanercept on the reactivation of HBV infection in HBsAg carriers with AS. Methods In this 48 weeks observation, HBsAg carriers with active AS (BASDAI ≥ 4 ) despite failed treatment with at least two NSAIDs and sulfasalazine (for patients with persistent peripheral arthritis) were studied. Patients must have normal liver function prior to etanercept therapy. All patients received the treatment of etanercept 50mg each week. For patients who had positive HBV load (>100 copy/ml) at baseline, lamivudin were prescribed preventively. Pre-existing NSAIDs and sulfasalazine were allowed. During the study, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and HBV load (polymerase chain reaction) were monitored every 6 weeks in the first 12 weeks and every 12 weeks after week 12. Increased AST/ALT and HBV load were managed and monitored according to expert opinion. After withdraw of etanercept due to any reason, monitoring of ALT, AST and HBV load must be conducted until normal result was obtained in 2 consecutive tests. Results Twenty-four patients (22 male, 1 female) were recruited. At baseline, seventeen patients (group 1, including 1 female) had normal viral load (Conclusions Etanercept therapy represent a safe and effective option for HBsAg carriers with AS refractory to traditional treatment. Prophylaxis strategy with more effective anti-viral drugs is recommended to reduce the risk of hepatitis B reactivation. Disclosure of Interest None Declared